Tempus AI stock fell Monday after the medical artificial intelligence company reported fourth-quarter results.
Tempus AI (TEM) reported a loss of 18 cents a share on revenue of $200.7 million. The company said it expects full year 2025 revenue of roughly $1.24 billion for its consolidated Tempus and Ambry Genetics business.
↑ X NOW PLAYING Indexes Down But Stocks Mixed; Progressive, Dutch Bros, Palantir In FocusChief Executive Eric Lefkofsky said the company's "investments in AI have positioned us well for the future."
But Tempus AI stock fell more than 8% to 63.72 in extended trading. The stock gained 2.2% to close at 69.57 in regular trading.
The shares have Relative Strength Rating of 93, according to IBD MarketSurge.
YOU MAY ALSO LIKE:
IBD 50's No. 2, Hims & Hers, Crashes 15% Despite Upbeat Earnings
Alibaba Stock Falls After China Tech Giant Pledges $52 Billion AI Spending Push
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。